Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye

To date, ocular antibody therapies for the treatment of retinal diseases rely on injection of the drug into the vitreous chamber of the eye. Given the burden for patients undergoing this procedure, less frequent dosing through the use of long-acting delivery (LAD) technologies is highly desirable. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesar, Devin, Luoma, Jacob, Wyatt, Emily A., Shi, Catherine, Shatz, Whitney, Hass, Philip E., Mathieu, Mary, Yi, Li, Corn, Jacob E., Maass, Katie F., Wang, Kathryn, Dion, Michelle Z., Andersen, Nisana, Loyet, Kelly M., van Lookeren Campagne, Menno, Rajagopal, Karthikan, Dickmann, Leslie, Scheer, Justin M., Kelley, Robert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680807/
https://www.ncbi.nlm.nih.gov/pubmed/28854082
http://dx.doi.org/10.1080/19420862.2017.1372078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680807/
https://www.ncbi.nlm.nih.gov/pubmed/28854082
http://dx.doi.org/10.1080/19420862.2017.1372078

Ejemplares similares